Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents
Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents
复制标题
DOI：
10.2533/chimia.2017.573
复制
发表时间：
2017-01-01
期刊：
影响因子：
1.2
通讯作者：
Marchetti, Fabio
中科院分区：
文献类型：
--
作者：
Biancalana, Lorenzo;Pampaloni, Guido;Marchetti, Fabio
式[Ru（eta（6）-arene）Cl-2（PTA）]（RAPTA）的钌（II）配合物是具有显著的抗转移和抗血管生成活性的潜在抗癌药物，其现在指向临床试验。这些化合物引起了极大的兴趣，各种RAPTA衍生物，通过氯取代和/或含有官能化的芳烃配体，和类似的RAPTA结构，但承载不同的磷配体的配合物已被合成和评价其抗癌活性。所有这些生物学相关的复合物的概述将给出，特别是参考的化合物所表现出的抗癌行为和可能的关系与结构方面。
Ruthenium(II) complexes of formula [Ru(eta(6)-arene)Cl-2(PTA)](RAPTA) are potential anticancer drugs with notable antimetastatic and antiangiogenic activity, which are now pointing to clinical trials. Following the great interest aroused by these compounds, a variety of RAPTA derivatives, obtained by chloride substitution and/or containing functionalized arene ligands, and complexes resembling the RAPTA structure but bearing different phosphorous ligands have been synthesized and evaluated for their anticancer activity. An overview of all of these biologically relevant complexes will be given, with particular reference to the anticancer behaviour exhibited by the compounds and the possible relationship with structural aspects.